Link to Full Article MIP Diagnostics Ltd. has today announced the launch of its COVID-19 nanoMIP for diagnostic sensors, a synthetic alternative to antibodies that offers ultra-high sensitivity for the next wave of COVID-19 antigen detecting devices. nanoMIPs are nanoscale Molecularly Imprinted Polymers, commonly known as synthetic antibodies. They are manufactured around a template molecule […]
Link to Full Article We are pleased to announce the appointment of Mike Dalrymple to the role of Head of Global Business Development at MIP Diagnostics on a consultancy basis. With over 30 years’ experience in diagnostics and therapeutics, Mike brings a wealth of knowledge and expertise to the business. Mike has a long track […]
Melbourne, Australia; 11 December 2020: Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce a successful $15 million placement (“Placement”), led by a $10m investment from experienced healthcare investor BioScience Managers through the BioScience Managers Translation Fund I (BMTFI). BMTFI has a mandate […]